Brahmer JR - Search Results

1

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR. Reck M, et al. Among authors: brahmer jr. J Clin Oncol. 2021 Jul 20;39(21):2339-2349. doi: 10.1200/JCO.21.00174. Epub 2021 Apr 19. J Clin Oncol. 2021. PMID: 33872070 Free PMC article. Clinical Trial.

2

Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions.

Lin TL, Brahmer JR. Lin TL, et al. Among authors: brahmer jr. Curr Oncol Rep. 2004 Jul;6(4):251-8. doi: 10.1007/s11912-004-0032-3. Curr Oncol Rep. 2004. PMID: 15161575 Review.

3

Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future.

Juergens RA, Brahmer JR. Juergens RA, et al. Among authors: brahmer jr. Curr Oncol Rep. 2005 Jul;7(4):248-54. doi: 10.1007/s11912-005-0046-5. Curr Oncol Rep. 2005. PMID: 15946582 Review.

4

Adjuvant treatment in non-small cell lung cancer: Where are we now?

Juergens RA, Brahmer JR. Juergens RA, et al. Among authors: brahmer jr. J Natl Compr Canc Netw. 2006 Jul;4(6):595-600. doi: 10.6004/jnccn.2006.0049. J Natl Compr Canc Netw. 2006. PMID: 16813727 Review.

5

Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.

Juergens R, Brahmer J, Ettinger D. Juergens R, et al. Cancer Chemother Pharmacol. 2007 Apr;59(5):621-9. doi: 10.1007/s00280-006-0304-8. Epub 2006 Aug 26. Cancer Chemother Pharmacol. 2007. PMID: 16937106 Clinical Trial.

6

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. Among authors: brahmer jr. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.

7

Second-line Therapy for advanced non-small-cell lung cancer.

Hann CL, Brahmer JR. Hann CL, et al. Among authors: brahmer jr. Curr Oncol Rep. 2006 Jul;8(4):243-7. doi: 10.1007/s11912-006-0027-3. Curr Oncol Rep. 2006. PMID: 17254522 Review.

8

Pleural mesothelioma metastatic to tongue.

Higginson DS, Brahmer J, Tufano RP, Bajaj GK. Higginson DS, et al. J Clin Oncol. 2007 May 20;25(15):2133-5. doi: 10.1200/JCO.2007.10.7086. J Clin Oncol. 2007. PMID: 17513821 No abstract available.

9

Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy.

Brahmer JR, Ettinger DS. Brahmer JR, et al. Respirology. 2007 May;12(3):320-5. doi: 10.1111/j.1440-1843.2007.01081.x. Respirology. 2007. PMID: 17539833 Review.

10

Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?

Juergens R, Brahmer J. Juergens R, et al. Curr Oncol Rep. 2007 Jul;9(4):255-64. doi: 10.1007/s11912-007-0031-2. Curr Oncol Rep. 2007. PMID: 17588349 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

250 results

Search Page